Literature DB >> 25347362

Species cross-reactivity of rheumatoid factors and implications for immunoassays.

Bettina E Holm1, Noreen Sandhu, Julie Tronstrøm, Magnus Lydolph, Nicole H Trier, Gunnar Houen.   

Abstract

Rheumatoid factors (RFs) are antibodies recognizing other antibodies usually by binding to the Fc part, while heterophilic antibodies (HAbs) are antibodies reacting with immunoglobulins (Igs) from other species. In particular, RFs have been found to cause false positive results in sandwich immunoassays. In this work, we analyzed RF-positive and RF-negative sera for content of cytokines and for heterophilic reactions by enzyme-linked immunosorbent assay and bead-based sandwich immunoassays. All sera, including those with RFs, contained insignificant amounts of cytokines and chemokines, but RF-positive sera showed large false positive values for several cytokines when analyzed by fluorescent bead-based multiplex immunoassays. This non-specific binding could be minimized by reagents designed to block HAbs, i.e. by selected animal IgGs. Furthermore, sera positive for RFs reacted with several animal IgGs, when these were immobilized on beads or coated on the polystyrene surface in enzyme-linked immunosorbent assays. This reaction could be inhibited by human IgG and by agents designed to inhibit heterophilic reactions (i.e. mixtures of IgGs from different species). In conclusion, RFs and HAbs represent an identical/overlapping set of antibodies, causing false positive reactions in sandwich and other immunoassays. Such assays must be conducted in the presence of appropriate blocking agents, e.g. HBR+, and must be carefully controlled.

Entities:  

Keywords:  Antibodies; cross-reactivity; false positive; heterophilic; immunoassays; multiplex; rheumatoid arthritis; rheumatoid factors

Mesh:

Substances:

Year:  2014        PMID: 25347362     DOI: 10.3109/00365513.2014.965738

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  6 in total

1.  Immunoglobulin G structure and rheumatoid factor epitopes.

Authors:  Sheila Lefoli Maibom-Thomsen; Nicole Hartwig Trier; Bettina Eide Holm; Kirsten Beth Hansen; Morten Ib Rasmussen; Anna Chailyan; Paolo Marcatili; Peter Højrup; Gunnar Houen
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

2.  Performance of a rapid immuno-chromatographic test (Schistosoma ICT IgG-IgM) for detecting Schistosoma-specific antibodies in sera of endemic and non-endemic populations.

Authors:  Julie Hoermann; Esther Kuenzli; Carmen Schaefer; Daniel H Paris; Silja Bühler; Peter Odermatt; Somphou Sayasone; Andreas Neumayr; Beatrice Nickel
Journal:  PLoS Negl Trop Dis       Date:  2022-05-27

Review 3.  Up-to-Date Applications of Microarrays and Their Way to Commercialization.

Authors:  Sarah Schumacher; Sandra Muekusch; Harald Seitz
Journal:  Microarrays (Basel)       Date:  2015-04-23

4.  Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren's syndrome.

Authors:  Peter Olsson; Kristin Skogstrand; Anna Nilsson; Carl Turesson; Lennart T H Jacobsson; Elke Theander; Gunnar Houen; Thomas Mandl
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

Review 5.  Hormone Immunoassay Interference: A 2021 Update.

Authors:  Khaldoun Ghazal; Severine Brabant; Dominique Prie; Marie-Liesse Piketty
Journal:  Ann Lab Med       Date:  2022-01-01       Impact factor: 3.464

6.  Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort.

Authors:  Johanna E Gehin; Rolf A Klaasen; Ellen S Norli; David J Warren; Silje W Syversen; Guro L Goll; Trine Bjøro; Tore K Kvien; Maria D Mjaavatten; Nils Bolstad
Journal:  Rheumatol Int       Date:  2021-05-04       Impact factor: 2.631

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.